Should Dividend Investors Eject Abbott Laboratories Stock?

Dividend aristocrat Abbott Labs  has has a long history of rewarding income investors, but after its transformation, is it still one of the sector's top dividend stocks? 

In this video, Motley Fool health-care analyst David Williamson will be grading well-known dividend stocks using a World Cup-inspired grading system: a yellow card is a warning for investors, a red card is an ejection, and a "goal" happens if the stock looks like a winner. 

Watch and find out the strengths and weaknesses of Abbott Labs, and whether investors should eject it.

Top dividend stocks for the next decade
The smartest investors know that dividend stocks simply crush their non-dividend-paying counterparts over the long term. That's beyond dispute. They also know that a well-constructed dividend portfolio creates wealth steadily, while still allowing you to sleep like a baby. Knowing how valuable such a portfolio might be, our top analysts put together a report on a group of high-yielding stocks that should be in any income investor's portfolio. To see our free report on these stocks, just click here now.

 

The article Should Dividend Investors Eject Abbott Laboratories Stock? originally appeared on Fool.com.

David Williamson owns shares of Abbott Laboratories and AbbVie. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Can't get enough business news?

Sign up for Finance Report by AOL and get everything from retailer news to the latest IPOs delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.